RE: Covid undervalues the potential of BAMS30 Jan 2021 03:07
Great post WeedyIan. As Adeptrix noted at the beginning of January,
'The current inventory of BAMS reagents have been configured for protein analysis in the fields of neurology, oncology and epigenetics. Over 30 assays are planned for release in Q1 2021.
Adeptrix will develop and commercialize BAMS assay kits for virology research and clinical diagnostics, both directly and via its strategic partners’ worldwide sales and marketing teams. The assays will be developed specifically to leverage the large installation base of MALDI instruments in Pharma and Academia.'
Hopefully Avacta's affirmers will play a big part in Adeptrix's continued growth and commercialization.